Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine + Rituximab vs Ibrutinib + Rituximab vs Ibrutinib in Untreated Older CLL Patients
NCT01886872Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2014
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of ibrutinib in chronic lymphocytic leukemia (CLL), sponsored by National Cancer Institute. Started Jan 2014; status: active, not recruiting.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01886872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01886872.